Single-Tablet Emtricitabine-Rilpivirine-Tenofovir as HIV Postexposure Prophylaxis in Men Who Have Sex with Men

Clinical Infectious Diseases

Volumn 61, Issue 8, 2015, Pages 1336-1341

  Foster, Rosalind ^a   McAllister, John ^b   Read, Tim R ^c,d   Pierce, Anna B ^e   Richardson, Robyn ^b   McNulty, Anna ^a,f   Carr, Andrew ^b  

^a Sydney Sexual Health Centre   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c MELBOURNE SEXUAL HEALTH CENTRE   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e ALFRED HOSPITAL   (Australia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Adherence; Completion; HIV; Postexposure prophylaxis; Rilpivirine

Indexed keywords

CREATININE; EMTRICITABINE PLUS RILPIVIRINE PLUS TENOFOVIR DISOPROXIL; PHOSPHATE; PROTEIN; TRIACYLGLYCEROL LIPASE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; TABLET;

ABDOMINAL PAIN; ACNE; ACUTE PANCREATITIS; ADULT; ANAL INTERCOURSE; ARTICLE; AUSTRALIA; CREATININE BLOOD LEVEL; DEPRESSION; DIARRHEA; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FOLLOW UP; FOOD; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MEN WHO HAVE SEX WITH MEN; MULTICENTER STUDY; NAUSEA; NONHUMAN; OPEN STUDY; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; PILL; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; PROTEIN URINE LEVEL; SELF REPORT; SIDE EFFECT; TABLET; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VIRUS LOAD; VOMITING; BLOOD; CLINICAL TRIAL; DRUG ADMINISTRATION; HIV INFECTIONS; MALE HOMOSEXUALITY; MIDDLE AGED; YOUNG ADULT;

ADULT; ANTI-HIV AGENTS; AUSTRALIA; DRUG ADMINISTRATION SCHEDULE; EMTRICITABINE, RILPIVIRINE, TENOFOVIR DRUG COMBINATION; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; POST-EXPOSURE PROPHYLAXIS; TABLETS; YOUNG ADULT;

EID: 84943225134     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ511     Document Type: Article

References (19)

1. Centers for Disease Control and Prevention. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep 2005; 54(RR-2):1-20.
2. European AIDS Clinical Society. Guidelines version 7.1 November 2014. Available at: http://www.eacsociety.org/files/guidelines-english- 71-141204.pdf. Accessed 9 July 2015.
3. World Health Organization. Guidelines on post-exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children: Recommendations for a public health approach. Supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Available at: http://apps.who.int/iris/bitstream/10665/145719/1/9789241508193-eng.pdf?ua=1&ua=1. Accessed 9 July 2015.
4. Benn P, Fisher M, Kulasegaram R; BASHH PEPSE Guidelines Writing Group Clinical Effectiveness Group. UK guideline for the use of postexposure prophylaxis for HIV following sexual exposure (2011). Int J STD AIDS 2011; 22:695-708.
5. Australasian Society for HIV Medicine (ASHM). National guidelines for post-exposure prophylaxis after non-occupational and occupational exposure to HIV. Available at: http://www.ashm.org.au/pep-guidelines. Accessed 8 July 2015.
6. Kuhar DT, Henderson DK, Struble KA, et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol 2013; 34:875-92.
7. Lee FJ, Amin J, BlochM, Pett SL, Marriott D, Carr A. Skeletalmuscle toxicity associated with raltegravir-based combination anti-retroviral therapy in HIV-infected adults. J Acquir Immun Defic Syndr 2013; 62:525-33.
8. McAllister J, Read P, McNulty A, Tong WW, Ingersoll A, Carr A. Raltegravir-emtricitabine-tenofovir as HIV nonoccupational postexposure prophylaxis in men who have sex with men: safety, tolerability and adherence. HIV Med 2013; 15:13-22.
9. Savage J; National PEP Guidelines Reference Group. Literature review for the national guidelines for post-exposure prophylaxis after non-occupational and occupational exposure to HIV. Sydney, NSW: Australasian Society for HIV Medicine, 2011. Available at: http://www.ashm.org.au/pep-guidelines. Accessed 9 July 2015.
10. Ford NF, Irvine C, Shubber Z, et al. Adherence to HIV postexposure prophylaxis: a systematic review and meta-analysis. AIDS 2014; 28:2721-7.
11. Ramjan R, Calmy A, Vitoria M, et al. Systematic review and meta-analysis: patient and programme impact of fixed-dose combination antiretroviral therapy. Trop Med Int Health 2014; 19:501-13.
12. Nachega JB, Parienti J-J, Olalekan AU, et al. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials. Clin Infect Dis 2014; 58:1297-307.
13. Hendrix CW. Exploring concentration response in HIV pre-exposure prophylaxis to optimize clinical care and trial design. Cell 2013; 155:515-8.
14. Cohen CJ, Molina J-M, Cassetti I, et al. Week 96 efficacy and safety of rilpivirine in treatment naïve, HIV-1 patients in two phase III randomized trials. AIDS 2013; 27:939-50.
15. Rilpivirine (Edurant) FDA-approved label 2011. US prescribing information for Edurant (rilpivirine). Available at: http://aidsinfo.nih.gov/drugs/426/edurant/0/professional. Accessed 9 July 2015.
16. Donnell D, Baeten JM, Bumpus NN, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr 2014; 66:340-8.
17. Hendrix CW, Andrade A, Kashuba AD, et al. Tenofovir-emtricitabine directly observed dosing: 100% adherence concentrations (HPTN 066) [Abstract 104]. In: 21st Conference on Retroviruses and Opportunistic Infections, Boston, MA, 3-6 March 2014.
18. Leal L, Leon A, Torres B, et al. Tenofovir/emtricitabine plus LPV/r vs MVC or raltegravir for PEP: 2 randomized trials. In: Program and abstracts of the Conference on Retroviruses and Opportunistic Infections-International Antiviral Society-USA, Seattle, WA, 2015:959.
19. The Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report, 2014:45. Available at: https://kirby.unsw.edu.au/sites/default/files/hiv/resources/ASR2014. pdf. Accessed 9 July 2015.